Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) EPS (Weighted Average and Diluted) (2016 - 2025)

Prestige Consumer Healthcare has reported EPS (Weighted Average and Diluted) over the past 16 years, most recently at $0.97 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 20.49% year-over-year to $0.97; the TTM value through Dec 2025 reached $3.79, down 11.24%, while the annual FY2025 figure was $4.29, 2.88% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.97 at Prestige Consumer Healthcare, up from $0.86 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.22 in Q4 2024 and troughed at -$4.79 in Q1 2023.
  • A 5-year average of $0.72 and a median of $1.02 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 569.61% in 2023 and later soared 120.46% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.99 in 2021, then increased by 5.05% to $1.04 in 2022, then grew by 1.92% to $1.06 in 2023, then grew by 15.09% to $1.22 in 2024, then dropped by 20.49% to $0.97 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for PBH at $0.97 in Q4 2025, $0.86 in Q3 2025, and $0.95 in Q2 2025.